MedTrace Logo

Baseline Concentration of Direct Oral Anticoagulant and Incidence of Adverse Event Measure And See (MAS)

NCT03803579 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2023-07-20

No results posted yet for this study

Summary

The MAS Study is an observational, multicentre, prospective cohort study in Non valvular Atrial fibrillation (NVAF) patients treated with one of the direct oral anticoagulants (DOACs) available in Italy for NVAF patients.

The general aim is to deepen the knowledge of DOAC treatment in NVAF patients, by measuring the plasma concentration of anticoagulant drugs and their correlation with any adverse events that may occur during treatment.

Conditions

Sponsors & Collaborators

  • Arianna Anticoagulazione Foundation

    lead OTHER

Principal Investigators

  • Sophie Testa, MD · UUOO Lab Analisi Chim Cliniche Microb-Centro Emostasi, ASST-Cremona Italy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-09
Primary Completion
2022-05-30
Completion
2023-05-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03803579 on ClinicalTrials.gov